Sep 17, 2020

Coronary Artery Disease

Information about coronary artery disease (CAD) and its minimally invasive treatment with the Resolute Drug-Eluting Stent (DES) Platform.

The following media kits are made available to provide reporters with background information on the range of Medtronic therapies and the conditions they treat.

 
Feb 26, 2018
Medtronic Launches First 2.0 mm Drug-Eluting Stent in United States Designed to Treat Patients with Small Vessels
FDA Approved, Resolute Onyx 2.0 mm DES Technology Tackles Clinical Challenge of Treating Coronary Artery Disease in Previously Untreatable Patients

DUBLIN - February 26, 2018 - Designed specifically for small vessels, Medtronic plc (NYSE: MDT) today announced the U.S. Food and Drug Administration (FDA) approval and U.S. launch of the Resolute...
 
May 1, 2017
Medtronic Launches Resolute Onyx™ Drug-Eluting Stent In United States Following FDA Approval Becoming First DES Available In 4.5 mm And 5 mm Sizes
Engineered for Exceptional Deliverability, Advanced DES Technology Features Thinner Struts, Enhanced Visibility and the Broadest Size Matrix in the U.S.

DUBLIN – May 1, 2017 – Medtronic plc (NYSE: MDT) today announced the U.S. Food and Drug Administration (FDA) approval and U.S. launch of the Resolute Onyx™ Drug-Eluting Stent (DES). The...
 
Feb 1, 2016
Medtronic Adds New Resolute Onyx(TM) Drug-Eluting Stent Sizes and Expands Indications
New Extra-Large Vessel Stent Sizes and Indications in the EU Expand Treatment Options for Patients with Coronary Artery Disease

DUBLIN - February 1, 2016 - Medtronic plc (NYSE: MDT) today announced the recent CE (Conformité Européene) Mark and commercial launch for an expanded size matrix of the Resolute Onyx DES, a next...